Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NBP vs NVCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NBP Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

NBP Overall Winner 6-Pillar Tally: NBP 3 – 2 NVCT (1 Tie) Matrix Metrics: NBP 5 – 2 NVCT

As of Nov 16, 2026, NBP (NBP) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NBP carries a Unified Composite Score of 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin), whereas NVCT carries 50.5/100 (HOLD) at $19.02 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile NVCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NBP vs NVCT
NBP US Equity Head-to-Head Winner
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
TTM Revenue N/A
Forward P/E 2.7x
Beta / 30D Vol 1.66β · 81% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 20
RSI-14: 20.1 · SMA20: $1.08 · SMA50: $1.31
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.02
-6.0% 1D
Market Cap $681.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.72β · 85% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 47.0 Fund 57.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 45
RSI-14: 44.5 · SMA20: $19.64 · SMA50: $20.49

6-Pillar Scorecard Institutional Category Breakdown (NBP 3 – 2 NVCT)

Columns: Metric · NBP · NVCT
1. Valuation Multiples NBP
Forward P/E 2.7x N/M
Trailing P/E 2.7x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale NVCT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $96.3M $681.6M
3. Profitability & Quality NBP
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.1% -67.0%
4. Balance Sheet & Cash Flow NBP
Cash Generation (TTM) N/A -$40M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.73 Book/Sh · -59.1% ROE $3.68 Book/Sh · -67.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NVCT
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 72.4% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NBP (5) vs NVCT (2)
Institutional Metric NBP NVCT Criterion Row Edge
Market Capitalization
Scale
$96.3M $681.6M Larger Scale NVCT
Trailing P/E Ratio
Valuation
2.7x N/M Lower Multiple NBP
Forward P/E Ratio
Valuation
2.7x N/M Lower Multiple NBP
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.1% -67.0% Higher ROE NBP
52-Week Range Position
Momentum
0% ($1–$5) 56% ($6–$29) Stronger Trend NVCT
Beta / 30D Volatility
Risk Regime
1.66β · 81% Vol 0.72β · 85% Vol Lower Realized Risk NBP
Unified Institutional Score
Composite Signal
51.9 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite NBP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.73 Book/Sh · -59.1% ROE) -$40M ($3.68 Book/Sh · -67.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVCT +39.32 pp
NBP: -37.04% · NVCT: +2.28%
3M Horizon NVCT +49.02 pp
NBP: -58.03% · NVCT: -9.01%
6M Horizon NVCT +136.54 pp
NBP: -53.61% · NVCT: +82.93%
1Y Horizon NVCT +302.35 pp
NBP: -80.98% · NVCT: +221.37%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBP vs NVCT. Trailing 12-month operating profitability (NBP 0.0% vs NVCT 0.0%) and valuation multiples (NBP 2.7x vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.1% · 2.7x
NVCT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-67.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVCT BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 72.4%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact NVCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NVCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $681.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NBP vs NVCT Key Questions & Quantitative Answers

As of Nov 16, 2026, NBP (NBP) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NBP carries a Unified Composite Score of 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin), whereas NVCT carries 50.5/100 (HOLD) at $19.02 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile NVCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVCT leads the Growth & Scale pillar: NBP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NVCT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NBP generates N/A in USD-normalized revenue versus N/A for NVCT. In operating R&D and SG&A reinvestment, NBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NVCT.

NBP screens cheaper on headline valuation multiples. NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NBP (-59.1% ROE) versus NVCT (-67.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk). By comparison, NVCT carries 72.4% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.72β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.